Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
SeaStar Medical Holding Corp - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
ICU
Nasdaq
3841
https://seastarmedical.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for SeaStar Medical Holding Corp
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
- Mar 27th, 2024 12:30 pm
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
- Mar 12th, 2024 12:30 pm
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
- Mar 11th, 2024 8:05 pm
Q4 2023 Nuwellis Inc Earnings Call
- Mar 6th, 2024 3:44 am
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
- Feb 27th, 2024 1:30 pm
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
- Feb 22nd, 2024 12:58 pm
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
- Feb 22nd, 2024 12:53 pm
Unleash Massive Returns With These 3 Top Penny Stocks
- Feb 22nd, 2024 11:15 am
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
- Feb 1st, 2024 1:30 pm
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
- Jan 26th, 2024 1:05 pm
SeaStar Medical Appoints David A. Green as Chief Financial Officer
- Jan 11th, 2024 9:05 pm
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
- Jan 9th, 2024 1:30 pm
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
- Dec 28th, 2023 1:30 pm
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
- Dec 13th, 2023 1:30 pm
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
- Nov 14th, 2023 9:04 pm
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
- Oct 31st, 2023 12:00 pm
Discover the Next Nokia: 3 Penny Stocks With Big Potential
- Oct 31st, 2023 1:00 am
FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients
- Oct 30th, 2023 12:00 pm
FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
- Oct 18th, 2023 12:30 pm
SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
- Oct 5th, 2023 12:30 pm
Scroll